Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel

The introduction of new therapeutic agents for multiple myeloma (MM), including proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, has improved the outcomes of patients but, in parallel, has changed the frequency and epidemiology of thrombotic events. Thrombosis is now a signi...

Descripción completa

Detalles Bibliográficos
Autores principales: De Stefano, Valerio, Larocca, Alessandra, Carpenedo, Monica, Cavo, Michele, Di Raimondo, Francesco, Falanga, Anna, Offidani, Massimo, Petrucci, Maria Teresa, Ruggeri, Marco, Santi, Roberto Mario, Barosi, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Guideline Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614522/
https://www.ncbi.nlm.nih.gov/pubmed/35861017
http://dx.doi.org/10.3324/haematol.2022.280893

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614522/
https://www.ncbi.nlm.nih.gov/pubmed/35861017
http://dx.doi.org/10.3324/haematol.2022.280893

Ejemplares similares